Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Ligand Pharmaceuticals Inc (NASDAQ:LGND)

107.38
Delayed Data
As of 4:00pm ET
 +7.00 / +6.97%
Today’s Change
87.50
Today|||52-Week Range
139.79
+5.68%
Year-to-Date
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates
Feb 24 / Zacks.com - Paid Partner Content
Forget Alexion, Buy these 4 Biotech Stocks Instead
Feb 20 / Zacks.com - Paid Partner Content
Drug Stocks Q4 Earnings Slated for Feb 23: BMRN, ICPT & More
Feb 22 / Zacks.com - Paid Partner Content
3 Biotechs With Tremendously Promising Pipelines
Feb 15 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close100.38
Today’s open99.29
Day’s range99.29 - 107.94
Volume989,897
Average volume (3 months)313,717
Market cap$2.1B
Dividend yield--
Data as of 4:00pm ET, 02/27/2017

Growth & Valuation

Earnings growth (last year)-101.02%
Earnings growth (this year)+98.45%
Earnings growth (next 5 years)+35.00%
Revenue growth (last year)+51.53%
P/E ratio383.5
Price/Sales19.42
Price/Book--

Competitors

 Today’s
change
Today’s
% change
AGIOAgios Pharmaceutical...+2.54+5.31%
PTLAPortola Pharmaceutic...+1.49+4.45%
SAGESAGE Therapeutics In...+6.51+10.45%
PRTAProthena Corporation...+4.56+8.53%
Data as of 3:59pm ET, 02/27/2017

Financials

Next reporting dateMay 3, 2017
EPS forecast (this quarter)$1.31
Annual revenue (last year)$109.0M
Annual profit (last year)-$2.4M
Net profit margin-2.17%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John L. Higgins
President &
Chief Operating Officer
Matthew W. Foehr
Corporate headquarters
San Diego, California

Forecasts


Search for Jobs